지씨지놈
Financials
Valuation Metrics
지씨지놈's Market Cap is ₩1206B. Ranked #1107 of 2,436 in KR market (top 45%), #572 of 1,649 on KOSDAQ (top 35%), #130 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 56%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 120.62B KRW | KR#1,107/2,436 Sec#130/234 |
| Revenue | 31.53B KRW | KR#2,009/2,436 Sec#137/234 |
| Net Income | 4.04B KRW | KR#1,194/2,436 Sec#80/234 |
| Total Assets | 84.63B KRW | KR#1,867/2,436 Sec#155/234 |
| Net Assets | 78.27B KRW | KR#1,574/2,436 Sec#130/234 |
| Value | ||
| P/E | 29.82x | KR#1,249/2,436 Sec#74/234 |
| P/B | 1.54x | KR#1,806/2,436 Sec#130/234 |
| P/S | 3.83x | KR#2,073/2,436 Sec#135/234 |
| EV/EBITDA | 69.20x | KR#1,415/2,436 Sec#97/234 |
| FCF Yield | 0.82% | KR#1,156/2,436 Sec#84/234 |
| Profitability | ||
| ROE | 5.17% | KR#977/2,436 Sec#73/234 |
| ROA | 4.78% | KR#677/2,436 Sec#53/234 |
| Op. Margin | 3.92% | KR#1,072/2,436 Sec#83/234 |
| Financial Health | ||
| Debt Ratio | 108.12% | KR#399/2,436 Sec#57/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | 985.6M KRW | KR#1,147/2,436 Sec#87/234 |
| Cash | 35.12B KRW | KR#921/2,436 Sec#61/234 |
| Current Ratio | 18.59x | KR#32/2,436 Sec#12/234 |
| Net Debt/EBITDA | -28.42x | KR#21/2,436 Sec#1/234 |
| Performance | ||
| 1Y Return | -34.95% | KR#1,702/2,436 Sec#149/234 |
| 1M Return | 6.25% | KR#406/2,436 Sec#31/234 |
| From 52W High | -46.43% | KR#1,036/2,436 Sec#83/234 |
| 1Y MDD | -56.42% | KR#1,222/2,436 Sec#98/234 |
| Trading | ||
| Volume | 132,873 shares | KR#778/2,436 Sec#75/234 |
| Foreign Own. | 4.30% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 199 KRW | KR#1,203/2,436 Sec#84/234 |
| BPS | 3,344 KRW | KR#1,736/2,436 Sec#132/234 |
Company Info
GC Genome, established in 2013, is a specialized clinical genomics analysis company that listed on KOSDAQ under special provisions for technology growth companies in 2025. It offers customized molecular diagnostic solutions covering the entire life cycle in four business areas, including obstetrics examinations, and supplies genomics services to domestic tertiary general hospitals and clinics. The company is expanding its domestic and international business, including entering the United States and Thailand, strengthening service quality through technology advancement, and diversifying its product portfolio. GC Genome is headquartered in Yongin-si, Gyeonggi-do.